title: Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies.
authors.affiliation: Section of Gynecologic Medical Therapeutics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 401, Houston, TX 77030, USA. cverschr@mdanderson.org
authors.forename: C F
authors.initials: CF
authors.lastname: Verschraegen
authors.forename: M
authors.initials: M
authors.lastname: Vincent
authors.forename: J L
authors.initials: JL
authors.lastname: Abbruzzese
authors.forename: D
authors.initials: D
authors.lastname: Siegler
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
authors.forename: E
authors.initials: E
authors.lastname: Loyer
authors.forename: A P
authors.initials: AP
authors.lastname: Kudelka
authors.forename: E
authors.initials: E
authors.lastname: Rubin
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004357:Drug Synergism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: C079905:rubitecan; D002945:Cisplatin; D002166:Camptothecin